The first preliminary analysis [20] of SARS-CoV-2 IgM and IgG indicated that the antibody response in COVID-19 patients is similar to seroconversion kinetics indicated with Middle East respiratory syndrome (3 weeks after symptoms started) [21] and with severe acute respiratory syndrome (93% of patients seroconverted at an average of 20 days from symptom onset) [22], if not earlier than, these times. This evidence concerns the gene CD40LG and COVID-19.